2-[2-[3-[2-(1,3-Dioxobenzo[de]isoquinolin-2-yl)ethyl-methylamino]propyl-methylamino]ethyl]benzo[de]isoquinoline-1,3-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 2-[2-[3-[2-(1,3-Dioxobenzo[de]isoquinolin-2-yl)ethyl-methylamino]propyl-methylamino]ethyl]benzo[de]isoquinoline-1,3-dione
• 化学式: C₃₃H₃₂N₄O₄
• 分子量: 548.6
• InChiKey: QLMDOGSYIWUJHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  81.2
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP0714387B1

  公开（公告）日：1998-05-27
• Antibody drug conjugates and methods
  申请人：Gazzard J. Lewis

  公开号：US20070134243A1

  公开（公告）日：2007-06-14

  The invention relates to antibody drug conjugate (ADC) compounds represented by Formula I: Ab-(L-D) p I where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked by a linker (L) to an antibody (Ab). The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the multiplication of a tumor cell or cancer cell including administering to a patient an effective amount of a Formula I ADC.
• US7947839B2
  申请人：——

  公开号：US7947839B2

  公开（公告）日：2011-05-24